Showing results (221-230 of 285) with videos related to

Sort By:
Pageof 29
The Cochrane Database of Systematic Reviews|September 30, 2015
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adultsTayla L McCloud, Caroline Caddy, Janina Jochim, et al.
Physics in Medicine and Biology|December 9, 2008
The use of magnetic field effects on photosensitizer luminescence as a novel probe for optical monitoring of oxygen in photodynamic therapyO Mermut, K R Diamond, J-F Cormier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2010
Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft modelsJohn J Tentler, Erica L Bradshaw-Pierce, Natalie J Serkova, et al.
Frontiers in Oncology|April 17, 2025
Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancerAnna R Schreiber, Stephen G Smoots, Marilyn M Jackson, et al.
Targeted Oncology|March 13, 2026
First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid MalignanciesAlbiruni Razak, Amit Mahipal, Jennifer R Diamond, et al.
Diabetologia|June 16, 2000
Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjectsD M Flavell, I Pineda Torra, Y Jamshidi, et al.
JAMA Oncology|October 23, 2018
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical TrialSylvia Adams, Jennifer R Diamond, Erika Hamilton, et al.
Investigational New Drugs|April 22, 2015
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumorsJennifer R Diamond, Benjamin Wu, Neeraj Agarwal, et al.
Cancer Medicine|October 16, 2020
Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer CenterJennifer A Weiss, Andrew Nicklawsky, Jodi A Kagihara, et al.
Investigational New Drugs|January 21, 2017
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week scheduleAntonio Jimeno, Manish R Sharma, Sergio Szyldergemajn, et al.
Pageof 29